10 studies found for:    EC-145
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
2 Completed Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
Condition: Cancer
Interventions: Drug: Vintafolide IV Bolus;   Drug: Vintafolide IV Infusion
3 Completed Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
Condition: Ovarian Cancer
Interventions: Drug: Vintafolide;   Drug: pegylated liposomal doxorubicin (PLD);   Other: EC20
4 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Conditions: Ovarian Cancer;   Endometrial Cancer
Interventions: Drug: Vintafolide;   Drug: Ertafolide
5 Terminated A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Condition: Advanced Cancer
Interventions: Drug: Vintafolide;   Drug: Carboplatin;   Drug: Paclitaxel
6 Enrolling by invitation Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Condition: Solid Tumors
Intervention: Drug: EC145
7 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
8 Suspended Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Condition: Ovarian Cancer
Interventions: Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20
9 Terminated A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Condition: Solid Tumor
Intervention: Drug: Vintafolide
10 Withdrawn Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel

Indicates status has not been verified in more than two years